tbuckley/cabot-search huggingface dataset:
Prevention of congenital rubella infection: a challenge for every country in Europe
Authors: N Crowcroft, R G Pebody
Journal: Eurosurveillance (2004)

The current issue of Eurosurveillance provides the common theme of the epidemiology and control of congenital rubella infection (CRI) across Europe. It provides a stark reminder that despite the availability of a safe and effective vaccine for many years, CRI - the consequence of rubella infection during pregnancy, remains an important public health problem both in the European Union and the wider WHO European Region. The following articles outline the various operational challenges facing national immunisation programmes in Europe. They vividly illustrate large differences in disease burden and inequalities in access to preventive health services both between and within countries. Four groups of countries can be distinguished.
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Authors: Hussein A Tawbi, Melissa Burgess, Vanessa Bolejack, Brian A Van Tine, Scott M Schuetze, James Hu, Sandra D'Angelo, Steven Attia, Richard F Riedel, Dennis A Priebat, Sujana Movva, Lara E Davis, Scott H Okuno, Damon R Reed, John Crowley, Lisa H Butterfield, Ruth Salazar, Jaime Rodriguez-Canales, Alexander J Lazar, Ignacio I Wistuba, Laurence H Baker, Robert G Maki, Denise Reinke, Shreyaskumar Patel
Journal: The Lancet Oncology (2017)
Combined activity of dasatinib (BMS-354825) and oxaliplatin in an orthotopic model of metastatic colorectal carcinoma
Authors: Donald P. Lesslie, Nila U. Parikh, Ami Shah, Justin M. Summy, Jose G. Trevino, David Hong, Nicholas J. Donato, Francis Y. Lee, Gary E. Gallick
Journal: Cancer Research (2006)

4745   The non-receptor protein tyrosine kinase, SRC has been implicated as a key regulator of tumor progression and metastasis in a variety of human malignancies, and is overactivated in a number of tumor types. Specifically, colorectal hepatic metastases exhibit markedly elevated SRC kinase activity as compared with normal colonic mucosa and primary tumors, and increased activity is predictive of poor prognosis. Thus, SRC inhibitors represent an attractive therapeutic target and, as such, will be entering clinical trial as single agents for metastatic colon cancer. In the current study, we investigated whether dasatinib (BMS-354825), a novel, oral, potent, multi-targeted kinase inhibitor of SRC and BCR-ABL, when combined with oxaliplatin, could inhibit growth of established hepatic colorectal tumors. Dasatinib monotherpay has already shown efficacy, and was well tolerated, in Philidelphia-chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia in a Phase I trial of patients who were imatinib-resistant/-intolerant; Phase II studies are ongoing in these patients. Phase I evaluation of dasatinib monotherapy in solid tumors is also ongoing. For the studies described herein, HT29 human colorectal carcinoma cells were injected directly into the liver, and treatment (dasatinib daily by oral gavage and oxaliplatin twice weekly via IP injection) was initiated 14 days later. Treatment with dasatinib alone (15mg/kg) or oxaliplatin (5mg/kg) alone reduced hepatic tumor volume by 31% and 35%, respectively. In contrast, treatment with the inhibitors combined at the same concentrations reduced hepatic tumor volume by 75%. Furthermore, treatment with dasatinib in combination with Oxaliplatin was associated with markedly decreased microvessel density, relative to either inhibitor alone. Whereas increased necrosis was evident relative to either agent alone, there was no increase in apoptosis as determined by TUNEL staining of tumor sections. Treatment with dasatinib but not oxaliplatin decreased expression of phospho SRC419, indicative of efficacy on activated SRC, demonstrating that dasatinib effectively inhibited SRC by the above-described regimen. In conclusion, the combination of oxaliplatin, currently in clinical trials for metastatic colon cancers, and a SRC inhibitor, also in clinical trials for a variety of solid tumors, could prove less toxic and more efficacious than current therapeutic regimens.
The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
Authors: Samuel T. Wilkinson, Elizabeth D. Ballard, Michael H. Bloch, Sanjay J. Mathew, James W. Murrough, Adriana Feder, Peter Sos, Gang Wang, Carlos A. Zarate, Gerard Sanacora
Journal: American Journal of Psychiatry (2017)

Objective: Suicide is a public health crisis with limited treatment options. The authors conducted a systematic review and individual participant data meta-analysis examining the effects of a single dose of ketamine on suicidal ideation. Method: Individual participant data were obtained from 10 of 11 identified comparison intervention studies that used either saline or midazolam as a control treatment. The analysis included only participants who had suicidal ideation at baseline (N=167). A one-stage, individual participant data, meta-analytic procedure was employed using a mixed-effects, multilevel, general linear model. The primary outcome measures were the suicide items from clinician-administered (the Montgomery-Åsberg Depression Rating Scale [MADRS] or the Hamilton Depression Rating Scale [HAM-D]) and self-report scales (the Quick Inventory of Depressive Symptomatology–Self Report [QIDS-SR] or the Beck Depression Inventory [BDI]), obtained for up to 1 week after ketamine administration. Results: Ketamine rapidly (within 1 day) reduced suicidal ideation significantly on both the clinician-administered and self-report outcome measures. Effect sizes were moderate to large (Cohen’s d=0.48–0.85) at all time points after dosing. A sensitivity analysis demonstrated that compared with control treatments, ketamine had significant benefits on the individual suicide items of the MADRS, the HAM-D, and the QIDS-SR but not the BDI. Ketamine’s effect on suicidal ideation remained significant after adjusting for concurrent changes in severity of depressive symptoms. Conclusions: Ketamine rapidly reduced suicidal thoughts, within 1 day and for up to 1 week in depressed patients with suicidal ideation. Ketamine’s effects on suicidal ideation were partially independent of its effects on mood, although subsequent trials in transdiagnostic samples are required to confirm that ketamine exerts a specific effect on suicidal ideation. Additional research on ketamine’s long-term safety and its efficacy in reducing suicide risk is needed before clinical implementation.
Antiproliferative and antimetastatic potential of some methoxyflavonoids derived from Artemisia plants
Authors: Do-Hee Kim, Min-Jung Kim, Hye-Kyung Na, Young-Joon Surh
Journal: Cancer Research (2008)

1248  Extracts of Artemisia plants have been reported to possess anti-inflammatory and anti-oxidative activities. We investigated the potential chemopreventive effects of some methoxyflavonoids derived from Artemisia plats. We observed that anti-proliferative effect of eupatilin (5,7-dihydroxy-3,4,6-tri-methoxy-flavone), one of the pharmacologically active ingredients derived from Artemisia asiatica, was mediated by blocking cell cycle progression which appears to be attributable in part to inhibition of Ras/Raf/ERK activation and AP-1 DNA binding in H-ras transformed human breast epithelial (MCF10A-ras) cells. In addition, we examined an antimetastatic potential of eupatilin in TNF-α-treated human breast epithelial (MCF-10A) cells. Tumor necrosis factor (TNF)-α stimulates uPA expression, thereby making the cells aggregate and to attain compaction. Cell-cell dissociation induced by TNF-α has been linked to the disordered expression of cadherin/β-catenin at the sites of cell-cell contact. Si-RNA knock down of β-catenin down-regulated uPA expression in TNF-α-stimulated MCF-10A cells. Eupatilin inhibited TNF-α-induced nuclear localization of β-catenin and Tcf-4 DNA binding activity as well as uPA expression in MCF-10A cells. Moreover, eupatilin significantly inhibited the TNF-α-induced invasiveness of MCF-10A cells as evidenced by the reduced migration and wound healing. Thus, eupatilin can exert anti-metastatic effects by targeting uPA and β-catenin signaling mediated by TNF-α. Furthermore, we examined the ability of jaceosidin, a eupatilin analog isolated from Artemisia argyi, to induce apoptosis in MCF10A-ras cells. Jaceosidin inhibited the growth of MCF10A-ras cells to a greater extent than eupatilin. Jaceosidin-induced apoptosis was mediated by intracellular ROS accumulation in MCF10A-ras cells, which was blocked by the antioxidant N-acetylcysteine. Jaceosidin has an additional hydroxyl moiety at the 4′-position which was replaced by the methoxy group in eupatilin. To better assess the pro-apoptotic effects of jaceosidin, we analyzed the treated cells by the flow cytometry. MCF10A-ras cells treated with jaceosidin (100 μM) exhibited the increased proportion of hypodiploid or apoptotic cells. Jaceosidin treatment also decreased the ratio of pro-apoptotic Bax to the anti-apoptotic Bcl-2 and induced the cleavage of caspase-3 and poly(ADP-ribose)polymerase (PARP). Jaceosidin elevated expression of p53 and p21, while inhibited the activation of ERK1/2 which is an important component of cell survival pathways. In conclusion, the pro-apoptotic activity of jaceosidin is associated with ROS accumulation and inhibition of ERK1/2 activation in MCF10A-ras cells. Taken together, the above results suggest that some methoxyflavonoids derived from Artemisia plants have chemopreventive and chemotherapeutic potential in human mammary carcinogenesis.
SToRM: A clinical cohort to identify genetic variability related to metastatic phenotypes
Authors: D. Cox, E. Blanc, G. Romieu, M. Rios, C. Becuwe, C. Jouannaud, L. Chaigneau, M. Arnedos, H. Orfeuvre, T. Petit, N. Quenel Tueux, J-P. Jacquin, J-M. Ferrero, S. Abadie Lacourtoisie, F. Penault-Llorca, C. Segura-Ferlay, I. Moullet, T. Bachelot, X. Pivot
Journal: Annals of Oncology (2017)
Assessing Health Insurance Coverage Characteristics and Impact on Health Care Cost, Worry, and Access
Authors: Elyse R. Park, Anne C. Kirchhoff, Ryan D. Nipp, Karen Donelan, Wendy M. Leisenring, Gregory T. Armstrong, Karen A. Kuhlthau
Journal: JAMA Internal Medicine (2017)

Ellen B. Rubinstein, PhD; William L. Miller, MD; Shawna V. Hudson, PhD; Jenna Howard, PhD; Denalee O'Malley, PhD; Jennifer Tsui, PhD; Heather Sophia Lee, PhD; Alicja Bator, MPH; Benjamin F. Crabtree, PhD
Mortality Reduction Associated With β-Adrenoceptor Inhibition in Chronic Heart Failure Is Greater in Patients With Diabetes
Authors: Klaus K. Witte, Michael Drozd, Andrew M.N. Walker, Peysh A. Patel, Jessica C. Kearney, Sally Chapman, Robert J. Sapsford, John Gierula, Maria F. Paton, Judith Lowry, Mark T. Kearney, Richard M. Cubbon
Journal: Diabetes Care (2017)

OBJECTIVE Diabetes increases mortality in patients with chronic heart failure (CHF) and reduced left ventricular ejection fraction. Studies have questioned the safety of β-adrenoceptor blockers (β-blockers) in some patients with diabetes and reduced left ventricular ejection fraction. We examined whether β-blockers and ACE inhibitors (ACEIs) are associated with differential effects on mortality in CHF patients with and without diabetes. RESEARCH DESIGN AND METHODS We conducted a prospective cohort study of 1,797 patients with CHF recruited between 2006 and 2014, with mean follow-up of 4 years. β-Blocker dose was expressed as the equivalent dose of bisoprolol (mg/day) and ACEI dose as the equivalent dose of ramipril (mg/day). Cox regression analysis was used to examine the interaction between diabetes and drug dose on all-cause mortality. RESULTS Patients with diabetes were prescribed larger doses of β-blockers and ACEIs than were patients without diabetes. Increasing β-blocker dose was associated with lower mortality in patients with diabetes (8.9% per mg/day; 95% CI 5–12.6) and without diabetes (3.5% per mg/day; 95% CI 0.7–6.3), although the effect was larger in people with diabetes (interaction P = 0.027). Increasing ACEI dose was associated with lower mortality in patients with diabetes (5.9% per mg/day; 95% CI 2.5–9.2) and without diabetes (5.1% per mg/day; 95% CI 2.6–7.6), with similar effect size in these groups (interaction P = 0.76). CONCLUSIONS Increasing β-blocker dose is associated with a greater prognostic advantage in CHF patients with diabetes than in CHF patients without diabetes.
Milroy's Disease
Authors: Victor A. McKusick
Journal: JAMA (1968)

<h3>To the Editor:—</h3> Your editorial<sup>1</sup>gave an interesting account of Dr. Milroy of Omaha, who is eponymously memorialized in hereditary lymphedema. Dr. Thomas Findley, professor of medicine emeritus at the Medical College of Georgia, has told me that Milroy was his family's physician when he was growing up in Omaha. You might have mentioned that in 1928<sup>2</sup>Milroy published a followup on the family with lymphedema (which was not Dr. Findley's), which was first reported in 1892. The propositus was at that time still alive in his late 60's and was active as a missionary in Burma. Affected members of the family also included a clergyman in Florida (who had died before 1928), a congressman, a US senator, and a Chicago physician (also deceased), who had served as a surgeon in the US Navy in the Civil War. Surely affected members of that family are still living. The
JET-HCC: A phase 3 randomized, double-blind, placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinoma
Authors: S. Kobayashi, K. Ueshima, M. Moriguchi, T. Takayama, N. Izumi, H. Yoshiji, K. Hino, T. Oikawa, T. Chiba, K. Motomura, J. Kato, K. Yasuchika, A. Ido, J. Kinoshita, T. Sato, M. Ikeda, T. Okusaka, M. Kudo, K. Tamura, J. Furuse
Journal: Annals of Oncology (2017)
Tumor profiling from whole-genome and whole transcriptome sequencing to uncover gene fusions and structural variations in clinically relevant cancer genes.
Authors: Alexandra E Gylfe, Eve Shinbrot, Boyko Kakaradov, Wayne Delport, Corine K Lau, Subha Krishnan, Ally Perlina, Thanemozhi G Natarajan, Rachana Sainger, Kimberly Pelak, Paul Choppa, Janine Cooc, William Biggs, Heather L Smith, Brad Perkins, Daniel G Jones, Ramlah B Nehring, Ezra E.W. Cohen, Kenneth Joel Bloom
Journal: Journal of Clinical Oncology (2017)

e23118 Background: Current targeted cancer therapies rely on the identification of clinically relevant somatic alterations in the tumor. Hotspot gene-panels and exome sequencing are designed to quickly assess somatic variations in frequently mutated regions and/or the coding regions of relevant genes, but they have limited ability to detect complex genomic rearrangements or novel structural variations. Here, we describe an integrative and comprehensive approach to fully characterize the genomic complexity of solid tumors using high throughput whole genome sequencing (WGS) and whole transcriptome sequencing (RNA Seq). Methods: We performed WGS and high-depth sequencing of known cancer genes in 14 paired tumor-normal samples of a variety of tumor types. Tumor-specific somatic alteration assessments included protein-coding mutations, copy number variations, gene fusions and structural variants. In addition, RNA Seq data was analyzed to identify expressed somatic alterations. Results: We identified 2 novel fusion genes as well as important structural alterations which could have clinical and therapeutic implications. We described a novel BRAF fusion gene in a cholangiocarcinoma devoid of other known driver mutations. BRAF fusions have not been described previously in cholangiocarcinoma; this fusion may represent an alternative mechanism for MAPK activation and could be a useful drug target. We also identified a novel NTRK3 fusion partner in a glioblastoma tumor. This fusion may imply a novel mechanism for NTRK3 activation. Finally, we identified numerous tandem duplications in an ovarian cancer. Recent advances describe tandem duplication hotspots in ovarian cancer as a potential driver mechanism characterizing a specific mutational signature. Conclusions: Comprehensive genomics assessment of paired tumor-normal samples through whole-genome and transcriptome sequencing can yield additional clinically actionable genomic characteristics that may not be detected in whole-exome or hotspot gene-panel sequencing. These findings have the potential to aid in clinical decision making.
Dose escalation/expansion study to investigate the safety, pharmacokinetics, food effect, and antitumor activity of BGB-290 in patients with advanced solid tumors
Authors: J. Lickliter, L. Mileshkin, M. Voskoboynik, M. Millward, A. Freimund, T. Meniawy, T. Tang, R. Wei, M. Li, V. Paton
Journal: Annals of Oncology (2017)
OncotypeDX recurrence score and its relationship with basic immunohistochemistry for breast cancer patients in a Colombian cancer unit.
Authors: Fernando Herazo-Maya, Claudia Ramirez, Hector Garcia, Carlos Andres Ossa, Jorge Madrid, Mauricio Borrero, Gonzalo Angel, Carolina Echeverri, Monica Gil, Luis Rodolfo Gomez, Ana M. Gonzalez-Angulo
Journal: Journal of Clinical Oncology (2014)

e11548 Background: in developing countries, there is a need to evaluate the correlation between basic immunohistochemistry (IHC) and OncotypeDX recurrence score (RS) in breast cancer patients. Our primary aim was to determine if RS is predicted by estrogen receptor (ER), progesterone receptor (PR) and Ki67 levels in HER2-negative breast cancer. Secondary aims were to determine the relationship among age, tumor grade and tumor size with RS and analyze the concordance of ER and PR determined by IHC and RT-PCR. Methods: As part of a prospective cohort study we collected clinical, pathological and OncotypeDx information in 124 patients that underwent surgery for invasive breast cancer from November 2010 to October 2013 at the Instituto de Cancerologia-Clinica Las Americas. We applied multiple linear regression models to predict the RS. ER and PR by IHC or RT-PCR were considered as dichotomous variables. Pearson correlation coefficient (continuous variables) and Cohen´s Kappa index (ranking the values positive and negative) were used to determine the correlation and concordance between IHC and hormone receptors by RT-PCR. p-values <0.05 were considered significant. Results: Median age was 56 (range, 33-78). The linear regression model was not predictive of the RS (adjusted R2=0.341). Age, tumor size and histologic grade do not predict the RS in multivariate analyses (p>0.05). There was a correlation between ER and PR levels by IHC and RT-PCR (Pearson 0.45, P<0.001 and 0.72, p<0.01 respectively). Conclusions: IHC for ER, PR and Ki67 did not predict RS. There was a moderate correlation between IHC and RT-PCR for ER and PR. In this cohort, the RS appears to give additional biological information to standard prognostic factors.
Neratinib after trastuzumab (T)-based adjuvant therapy in early-stage HER2+ breast cancer (BC): 5-year analysis of the phase III ExteNET trial
Authors: M. Martin Jimenez, F.A. Holmes, B. Ejlertsen, S. Delaloge, B. Moy, H. Iwata, G. von Minckwitz, S. Chia, J. Mansi, C. Barrios, M. Gnant, Z. Tomasevic, N. Denduluri, R. Separovic, S-B. Kim, E.H. Jakobsen, R.P. Bryce, F. Xu, M. Buyse, A. Chan
Journal: Annals of Oncology (2017)
Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/refractory (rel/ref) small-cell lung cancer (SCLC)
Authors: Q.S.-C. Chu, C. van Herpen, N.B. Leighl, B. Markman, S. Clarke, R.A. Juergens, P. Basciano, D. Lathers, S. Tannenbaum-Dvir, K. Urbanska, G. Kollia, C. Darby, D. Williams, G. Kolaitis, N. Ready
Journal: Annals of Oncology (2017)
A phase II randomized trial of adjuvant chemotherapy for the patients completely resected pathological stage IB (T &gt; 5cm), II, IIIA non-small cell lung cancer comparing S-1 versus S-1 with cisplatin
Authors: T. Okamoto, T. Yano, M. Shimokawa, S. Takeo, K. Yamazaki, K. Sugio, M. Takenoyama, A. Nagashima, T. Tagawa, Y. Emi, Y. Maehara
Journal: Annals of Oncology (2017)
ARCHITECT® urine-Neutrophil Gelatinase-Associated Lipocalin (uNGAL) essay: New prognostic marker for clear cell Renal Cell Carcinoma (ccRCC)
Authors: F. Saint, F. Rose-Robert, Y.E. Herpe, P. de Sousa, H. Sevestre, G. Choukhroun, C. Amant
Journal: Annals of Oncology (2017)
Minimal Number of Anesthetic Treatments with Urethane Required to Induce Pulmonary Tumors
Authors: Paul S. Henshaw, Henry L. Meyer
Journal: JNCI Journal of the National Cancer Institute (1944)

Minimal Number of Anesthetic Treatments with Urethane Required to Induce Pulmonary Tumors Get access Paul S. Henshaw, Paul S. Henshaw senior radiobiologist Naional Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Henry L. Meyer Henry L. Meyer senior scientific aide Naional Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 4, Issue 5, April 1944, Pages 523–525, https://doi.org/10.1093/jnci/4.5.523 Published: 01 April 1944
Zoonoses in the European Union: origin, distribution and dynamics - the EFSA-ECDC summary report 2009
Authors: A Lahuerta, T Westrell, J Takkinen, F Boelaert, V Rizzi, B Helwigh, B Borck, H Korsgaard, A Ammon, P Mäkelä
Journal: Eurosurveillance (2011)

We present a summary of the main findings of the latest report of the European Food Safety Authority and European Centre for Disease Prevention and Control on zoonoses, zoonotic agents and food-borne outbreaks in the European Union (EU), based on data from 2009. Zoonoses are prevalent and widely distributed across several countries in the EU. The most important highlight of this report was the continuous decrease of human salmonellosis since 2005, probably due to effective control programmes in livestock.
Genomics of Immunotherapy-Associated Hyperprogressors—Response
Authors: Shumei Kato, Razelle Kurzrock
Journal: Clinical Cancer Research (2017)

Forschner and colleagues reported a patient with melanoma who experienced rapid increase in tumor burden while being treated with ipilimumab and nivolumab (246% and 377% increase compared with baseline after 1 and 3 months, respectively). The patient's tumor continued to spread quickly after
Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC) (on behalf of the North-Eastern German Society of Gynaecological Oncology, NOGGO)
Authors: J. Sehouli, A. Mustea, G. Oskay-Oezcelik, J. Grabowski, M. Keller, R. Richter, J. Harde, S. Klawitter, A. Wegenaer, O. Tomé, P. Wimberger
Journal: Annals of Oncology (2017)
GW28-e0121 Preconditioning with endoplasmic reticulum stress mitigates FFA induced 3T3-L1 adipocyte Inflammation
Authors: Min Wang, Shujie Yu, Bin Zhou, Yesheng Ling, Dinghui Liu, Lin Wu, Yongxiang Wu, Xiaoxian Qian
Journal: Journal of the American College of Cardiology (2017)